Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DBV Technologies SA

www.dbv-technologies.com

Latest From DBV Technologies SA

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.
Financing StartUps and SMEs

US FDA AdComm Win For Aimmune’s Palforzia Bodes Well For DBV’s Peanut Allergy Patch

Aimmune’s oral immunotherapy seems destined to come to market with a strict REMS, though analysts do not expect this will impact adoption. DBV is awaiting word on whether the FDA will review its second attempt at a BLA submission for Viaskin Peanut.

Advisory Committees Drug Review

Aimmune’s Peanut Allergy Immunotherapy Brings Safety Concerns To US FDA Panel

Palforzia was associated with a higher rate of adverse events, systemic allergic reactions, eosinophilic esophagitis and epinephrine use in controlled clinical trials; Allergenic Products Advisory Committee will weigh approval for patients ages 4-17 years with confirmed peanut allergy diagnosis.

Advisory Committees Drug Review

Keeping Track: Amarin And Nektar Signal Delays, DBV Returns, And Provention Notches A BTD

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Complete Response Letters
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Transdermal
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • DBV Technologies SA
  • Senior Management
  • Daniel Tassé , CEO
    Sébastien Robitaille, Deputy CFO
    Hugh A Sampson, MD, CSO & Interim CMO
    Susanna Mesa, CBO
  • Contact Info
  • DBV Technologies SA
    Phone: (33) 1 55 42 78 78
    177-181 avenue Pierre Brossolette
    Montrouge, 92120
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register